The PD1/PDL1 reverse signaling can activate the eIF2α/ATF4 pathway through IDO1 [17, 27] whose inhibitors are actively undergoing clinical trials in combination with anti-PD1 or anti-PDL1 antibodies to treat cancers [41]. Here, IDO1 is linked to cancer.